Clinical Trial Update: Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating vortioxetine for relapse prevention in adults with major depressive disorder; the study completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (Lu AA21004) (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2014-03-31